Saturday, July 11, 2026

pharma · Stroke · Pancreatic Cancer

Shandong Topscience Biotech

Shandong Topscience Biotech drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Rizhao, CN HQ
2005 Founded
15 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Rizhao, CN
Founded
2005
Employees
15
Programs
3
Drugs
4
Patents
0
Intelligence · Drug Pipeline

Shandong Topscience Biotech pipeline

Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Shandong Topscience Biotech drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

4 compounds
  1. Development asset linked to Shandong Topscience Biotech in public FDA and regional records.

  2. Development asset linked to Shandong Topscience Biotech in public FDA and regional records.

  3. ulipristal acetate

    Genito-urinary system and sex hormones (G03)

    US regulatory status: approved. Molecular target: Progesterone receptor.

    Target
    Progesterone receptor
    Mechanism
    Progesterone receptor modulator